Intra-Cellular Therapies

Intra-Cellular Therapies, established in 2002, is a specialized biopharmaceutical company dedicated to the research and development of novel small molecule drugs targeting neuropsychiatric and neurologic diseases. The firm focuses on addressing complex disorders of the central nervous system through rigorous clinical development and innovative discovery processes. By leveraging advanced therapeutic platforms, the company consistently works to deliver FDA-approved treatments that significantly improve patient outcomes within the global healthcare sector.

Operating with a dedicated workforce of 500-1,000 employees, the organization maintains a strategic operational footprint across two primary locations. Learn about Intra-Cellular Therapies' global headquarters for specific geographic details regarding their Bedminster, New Jersey facility. The company’s focused approach to clinical-stage research and commercialization allows it to compete effectively against major industry peers such as Neurocrine Biosciences, Acadia, and Supernus Pharmaceuticals, while maintaining a strong commitment to scientific excellence.

The company has demonstrated significant market presence, supported by a robust history of strategic stock issuances and share placements. Meet Intra-Cellular Therapies' team to understand the leadership driving these critical clinical advancements. With annual revenue reaching $680.9M, the firm continues to invest heavily in its pipeline of CNS-focused therapies. Explore financial highlights for a comprehensive overview of the company's fiscal performance, funding history, and long-term growth trajectory within the highly competitive biopharmaceutical landscape.